EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
Search
Mastitis dairy cows prevent antibiotic resistance
The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.
RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Equestrian sports horse health awareness Alex Hua Tian
Together with Olympian trailblazer and eventer Alex Hua Tian, we educate about equine health in China.
Health equity for underserved communities
Introducing initiatives that improve access to healthcare for underserved communities
Promising phase II results in chronic kidney disease
Boehringer Ingelheim’s investigation of novel compound on top of standard of care empagliflozin shows promising results for chronic kidney disease
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
One step further in fighting rabies in Vietnam
A expedition team set off to the Duc Hue District. The purpose? To vaccinate the entire dog and cat population of several villages.
It Takes 2
It Takes 2 people – a patient and a HCP, and 2 tests – a blood and a urine test–to help detect CKD. Early testing can drive earlier diagnosis and treatment.
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
CAROLINA-CARMELINA-Asia-analysis
CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Launch of first veterinary vaccines produced in China
Swine vaccine Ingelvac PRRS MLV, produced by Boheringer Ingelheim veterinary vaccine manufacturing plant in Taizhou is now officially supplied to the China market.
CARMELINA-elderly-analysis
CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
About Chronic Kidney Disease
CKD is very common and often goes undetected due to its silent nature. Risk factors include high blood pressure and type 2 diabetes.
Reimagining digital healthcare worldwide
How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Breathing hope: fighting the lung disease pulmonary fibrosis
The animation and accompanying article aims to draw attention to and raise awareness about pulmonary fibrosis, a disease often misdiagnosed an overlooked.
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Stem cell therapy for tendon and ligament injuries in horses
A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
Green Chemistry
Green Chemistry is critical for us as it balance the long-term sustainability of business, society, and the environment.